What is Premature Ejaculation Market?
Premature ejaculation (PE) happens when a man regularly reaches an orgasm much sooner during sexual intercourse. The main sign of PE is incapability to delay ejaculation for more than one minute after penetration. Premature ejaculation can be due to anxiety and personal problems that cause stress. An individualís relationship with his partner can get affected due to such kind of problem. It can be classified as lifelong premature ejaculation and acquired premature ejaculation. The other factors which can cause premature ejaculation are swelling of prostate or urethra, inherited traits and abnormal levels of neurotransmitters.
The market study is being classified by Type (Lifelong [Primary] and Acquired [Secondary]), by Application (Hospitals and Clinics) and major geographies with country level break-up.
Absorption Pharmaceuticals (United States), Plethora Solutions Holdings (United Kingdom), Ixchelsis (United Kingdom), NeuroHealing Pharmaceuticals Inc. (United States), Regent Pacific Group Limited (Hong Kong), Furiex Pharmaceuticals Inc. (United States), The Menarini Group (Italy), Royalty Pharma (Switzerland), Premature ejaculation (Italy), GlaxoSmithKline (United Kingdom), Innovus Pharmaceutical (United States), Pfizer Inc. (United States) and Futura Medical GlaxoSmithKline (United Kingdom) are some of the key players profiled in the study.
The premature ejaculation treatment market is competitive. The players in the market are focusing on launching new products, which in turn is expected to aid in growth of the market. Vendors of the premature ejaculation treatment are increasingly competing against each other based on factors such as the quality, pricing, market reach, and financial resources. Research Analyst at AMA predicts that United States and United Kingdom Players will contribute to the maximum growth of Global Premature Ejaculation market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Premature Ejaculation market by Type, Application and Region.
On the basis of geography, the market of Premature Ejaculation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Patient Willingness to seek Pharmaceutical Therapy Assistance
- Increasing Number of Patients Suffering with Premature Ejaculation Disorders
- Increasing Awareness about Premature Ejaculation
- Increasing Presence of Favorable Guidelines
- Introduction of Alternative Treatment Methods for Premature Ejaculation
- Pharmaceutical Advances in PE Drug Formulation Technology
- Associated Adverse Effects of PE Drugs
Market Leaders and some development strategies
December 21, 2019: Recordati acquires Tonipharm S.A.S. in France. The acquisition of Tonipharm represents a further opportunity to enhance the portfolio of Recordati in French self-medication market with well-known brands and good market shares.
Key Target AudienceSuppliers of Premature Ejaculation Drug, Wholesalers, distributers and retailers of Premature Ejaculation Drug, Healthcare Industry, Research Firms and Governmental Bodies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase